Current Report Filing (8-k)
October 06 2021 - 04:41PM
Edgar (US Regulatory)
false 0001488039 0001488039 2021-10-06
2021-10-06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
October 6, 2021 (October 6, 2021)
Atossa Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35610
|
|
26-4753208
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
107 Spring Street
Seattle, Washington
|
|
98104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(206) 325-6086
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuance to Section 12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.18 par value
|
ATOS
|
Nasdaq
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07 Submission of Matters to a
Vote of Security Holders
On September 7, 2021, Atossa Therapeutics, Inc. (the “Company”) convened a Special
Meeting of Stockholders (the “Special Meeting”) for the
purpose of voting on a proposal to increase authorized shares of
common stock by 100 million. As of that date, the proposal did not
have sufficient yes votes to pass so the Special Meeting was
adjourned until October 7, 2021 to allow additional time for
voting. As of October 6, 2021, approximately 58,445,262 votes were
cast in favor of the proposal which is approximately 46.2% of the
outstanding shares of common stock on the record date. A majority
of the issued and outstanding shares of common stock on the record
date must vote in favor of the proposal for it to pass. Because the
proposal has not garnered sufficient votes to pass, the Company is
withdrawing the proposal and is cancelling the Special
Meeting.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: October 6, 2021
|
Atossa Therapeutics, Inc.
|
|
|
|
|
|
By:
|
/s/ Kyle Guse
|
|
|
|
Kyle Guse
|
|
|
|
Chief Financial Officer, General Counsel and Secretary
|
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Dec 2022 to Jan 2023
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jan 2022 to Jan 2023